IPHA - Earnings announcements

Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma partnering and royalty structures IPH4502 (Nectin-4 ADC) continues to show preliminary anti-tumor activity with favorable safety profile to date; the maximum tolerated dose has been reached and enrollment in the Phase 1 dose escalation and cohort enrichment is nearing completion PACIFIC-9 Phase 3 trial, which includes monalizumab and is led by AstraZeneca, continues to advance toward a planned H2 2026 data readout IPH5201 (anti-CD39 antibody), developed in collaboration

Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Wednesday, May 13, 2026 at 1:30 p.m. CEST / 7:30 a.m. EDT, to provide an update on business progress for the first quarter of 2026. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Stéphanie Cornen, Vice President, Investor Relations, Communication & Commercial strategy Frédéric Lombard, Senior Vice President, Chief Financial Officer Event Details The live we

Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma partnering and royalty structures IPH4502 (Nectin-4 ADC) shows preliminary anti-tumor activity with favorable safety profile to date; Phase 1 cohort enrichment ongoing at active dose levels Monalizumab PACIFIC-9 Phase 3 trial, partnered with AstraZeneca, continues to advance toward a planned H2 2026 data readout IPH5201 (anti-CD39 antibody), partnered with AstraZeneca - Interim results of MATISSE Phase 2 trial in non-small cell lung cancer (NSCLC) have been selected for a

Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Thursday, March 26, 2026 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2025. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Stéphanie Cornen, Vice President, Investor Relations, Communication and Commercial Strategy Frédéric Lombard, Senior Vice President, Chief Financial Officer Details for t

Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sézary syndrome IPH4502 Nectin-4 ADC Phase 1 enrollment continues to progress well - pharmacologically active dose reached Monalizumab PACIFIC-9 on track to deliver data in H2 2026 Cash position of € 56.4 million1 as of September 30, 2025, anticipated cash runway until end Q3-2026 Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced its business update and financial results for the first nine mon

Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that the Company will hold a conference call on Thursday, November 13, 2025, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2025. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Stéphanie Cornen, Vice President, Investor Relation, Communication and Commercial Strategy Frédéric Lombard, Senior Vice President, Chief Financial Officer Details for the Virtual Event The liv

IPH4502 Nectin-4 ADC Phase 1 enrollment progressing well: Preclinical update and Trial In Progress presented at AACR Annual Meeting 2025 and ASCO 2025 Annual Meeting. Lacutamab BTD and Phase 3 preparation: FDA Breakthrough Therapy Designation (BTD) in February 2025 based on long-term follow-up data from the TELLOMAK clinical study presented at ASCO Annual Meeting 2025. Preparation of the confirmatory Phase 3 trial protocol is close to completion, following discussions with the FDA and EMA. Monalizumab: AstraZeneca Phase 3 PACIFIC-9 enrollment is completed and high level read-out is expected in H2 2026. Strategic focus: Innate Pharma plans to prioritize its investment in what it

Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Wednesday, September 17, 2025, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2025. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice President, Chief Financial Officer Details for the Virtual Event The live webcast will be available at the following link: https://events.q4inc.com/attende

€15 million investment by Sanofi, in addition to the ongoing partnership including the development of BCMA targeting ANKET® program in autoimmune indications First patient dosed in a Phase 1 study for IPH4502, Nectin-4 ADC in patients with selected advanced solid tumors. Presentations at AACR Annual Meeting 2025 and ASCO 2025 Annual Meeting FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome; long term follow up data from TELLOMAK Phase 2 to be presented at ASCO Annual Meeting 2025 Cash position of €72.5 million1 as of March 31, 2025, excluding the €15 million received from Sanofi, with a cash horizon to mid 2026 Conference call to b

Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Tuesday, May 13, 2025, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2025. In addition, members of the executive management team will be meeting with investors in New York and Boston from May 13 to May 14, 2025. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice President, Chief Financial Office

FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome New data, including lacutamab improved health-related quality of life data from TELLOMAK Phase 2 study in patients with cutaneous T cell lymphoma were presented at ASH 2024 The first patient was dosed in a Phase 1 study for IPH4502, Nectin-4 ADC in patients with selected advanced solid tumors IPH6501, Innate's proprietary ANKET® drug candidate, is being evaluated in a Phase 1/2 clinical trial in patients with B-cell non-Hodgkin's lymphoma Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) announced up to $7.9m investment from IFLI to support IPH6501 developm

Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Thursday, March 27, 2025 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2024. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice President, Chief Financial Officer Details for the Virtual Event The live webcast will be available at the following link: https://events.q4inc.com/

Jonathan Dickinson appointed Chief Executive Officer and Chairman of the Executive Board Encouraging initial FDA feedback received on lacutamab regulatory pathway Lacutamab health-related quality of life and translational data to be presented at the upcoming ASH Annual Meeting IPH4502, a Nectin-4 ADC received FDA clearance of the IND to be developed in solid tumors Preclinical data for proprietary tetra-specific NK cell engager IPH6501 and novel ADC IPH4502 presented at SITC Cash position of €96.4 million1 as of September 30, 2024, anticipated cash runway to end of 2025 Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET Regulatory News: Innate Pharma SA

Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that the Company will hold a conference call on Wednesday, November 13, 2024, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2024. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice President, Chief Financial Officer Arvind Sood, Executive Vice President, President of US Operations Details for the Virtual Event The live webcast will be availa

Positive results with lacutamab from TELLOMAK Phase 2 study in mycosis fungoides presented at ASCO 2024 NK-Cell engager SAR443579/IPH61011 first-in-human study advanced to Phase 2 and initiation of front-line AML Phase 1/2 combination study Updated data from dose-escalation part presented at EHA 2024 confirm clinical benefit and durable responses in patients with R/R AML IPH45, proprietary anti Nectin-4 ADC progressing towards Phase 1 in H2 2024 Monalizumab data from AstraZeneca-sponsored Phase 2 study in early NSCLC presented at WCLC Cash position of €102.1 million2 as of June 30, 2024, anticipated cash runway to end of 2025 Conference call to be held today at 2:00 p.m. CEST

Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Thursday, September 12, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2024. Participants during the call will be: Hervé Brailly, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice President, Chief Financial Officer Arvind Sood, Executive Vice President, President of US Operations Details for the Virtual Event The live webcast will be av

First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral presentation at AACR 2024 Progression of Sanofi-developed NK Cell Engager SAR443579/IPH6101 to Phase 2 in blood cancers Five ASCO Annual Meeting 2024 abstracts: Final TELLOMAK Phase 2 data for lacutamab in Mycosis Fungoides Two posters on IPH6501, Innate's second generation ANKET® in B‑cell Non-Hodgkin's Lymphoma AstraZeneca to present poster on updated results for monalizumab from Phase 2 stage III unresectable NSCLC trial Monalizumab SCLC Phase 2 MOZART trial poster Cash position of €113.9 million1 as of March 31, 2024 (not including the €4.0 million payment

Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2024. Participants during the call will be: Hervé Brailly, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice President, Chief Financial Officer Arvind Sood, Executive Vice President, President of US Operations Details for the Virtual Event The live webcast will be availa

Positive final results of lacutamab TELLOMAK Phase 2 trial in Sézary syndrome presented at ASH Annual Meeting 2023; final data in mycosis fungoides to be shared at an upcoming medical congress Licensing of a fourth NK cell engager ANKET® by Sanofi, triggering a €15m payment to Innate; ANKET® partnered assets progressing well with two molecules in clinical trials First patient dosed in Phase 1/2 clinical trial with IPH6501, a proprietary second generation ANKET® in B-cell Non-Hodgkin's Lymphoma IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, selected for oral presentation at AACR 2024 New Executive Board formed with Hervé Brailly, interim Chief Executive Officer, Yannis

Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Thursday, March 21, 2024 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2023. Participants during the call will be: Hervé Brailly, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice President, Chief Financial Officer Arvind Sood, Executive Vice President, President of US Operations Details for the Virtual Event The live web

Positive final results of lacutamab TELLOMAK Phase 2 trial in Sézary syndrome selected for oral presentation and preliminary data in Peripheral T Cell lymphoma to be displayed in a poster at ASH Annual Meeting 2023 ASH presentation on SAR443579/IPH6101, a potential first-in-class NKp46/CD16-based NK cell engager targeting CD123; the ANKET® platform lead asset and under development by partner Sanofi, which demonstrated clinical remissions IPH6501, Innate's proprietary tetra-specific ANKET®, progressing towards Phase 1 clinical trial in 2023 Cash position of €121.9 million1 as of 30 September 2023, anticipated cash runway into H2 2025 Conference call to be held today at 2:00 p.m.

Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that the Company will hold a conference call on Tuesday, November 14, 2023, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2023. Participants during the call will be: Mondher Mahjoubi, Chief Executive Officer Yannis Morel, Executive Vice President, Product Portfolio Strategy & Business Development Sonia Quaratino, Executive Vice President, Chief Medical Officer Frédéric Lombard, Senior Vice President, Chief Financial Officer Details for the Third Quarter 2023 Business Update Virtual Event Tuesday, November 14, 2023, at 2 p.m. CET / 8 a.m

Phase 1/2 dose escalation safety and preliminary efficacy of ANKET® NK cell engager, SAR'579/IPH6101, developed by Sanofi, showed it was well tolerated with observed clinical benefit in patients with R/R AML (ASCO 2023 annual meeting), FDA Fast Track Designation awarded Exclusive worldwide rights granted to Takeda to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies; $5m upfront payment to Innate and up to $410m in future milestones plus royalties Proprietary ANKET® IPH65 IND approved, progressing to Phase 1 Proprietary IPH45 ADC target, nectin-4 disclosed Innate announces new Chief Medical Officer, Sonia Quaratino Cash position

Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below. In addition, the Company will hold a conference call on Thursday, September 14, 2023, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2023. Citi's 18th Annual BioPharma Conference Event Date: September 6 – 7, Boston H.C. Wainwright 25th Annual Global Investment Conference Event Date: September 11 – 13, New-York Morgan Stanley 21st Annual Global Healthcare Conference Event Date: September 11 – 13, New-York First Half 2023 Financial

Exclusive worldwide rights granted to Takeda to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies; Innate to receive $5m upfront payment and eligible to up to $410m in future milestones plus royalties ANKET® assets in collaboration with Sanofi continue to progress; abstract for IPH6101/SAR'579 selected for oral presentation at ASCO 2023 annual meeting Cash position of €135.0 million1 as of March 31, 2023 (not including the $5 million payment from Takeda), anticipated cash runway into mid 2025 Conference call to be held today at 2:00 p.m. CEST / 8:00 a.m. EDT Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today

Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Wednesday, May 10, 2023 at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2023. Participants during the call will be: Mondher Mahjoubi, Chief Executive Officer Joyson Karakunnel, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Product Portfolio Strategy & Business Development Frédéric Lombard, Senior Vice President, Chief Financial Officer Details for the Virtual Event The live webcast will be available at the following link: https://events.q4inc.com/atte

Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKET® program and two additional targets, with €25 million payment Encouraging preliminary TELLOMAK Phase 2 efficacy data for lacutamab in advanced cutaneous T cell lymphoma in Sézary syndrome and mycosis fungoides First patient dosed in monalizumab PACIFIC-9 Phase 3 lung cancer clinical trial with $50M payment from AstraZeneca Cash position of €136.6 million2 as of December 31, 2022 (not including the €25 million payment from Sanofi), anticipated cash runway into mid 2025 Conference call to be held today at 2:00 p.m. CET / 9:00 a.m. EDT Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the

Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Thursday, March 23, 2023 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2022. Speakers during the call will be: Mondher Mahjoubi, Chief Executive Officer Joyson Karakunnel, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Product Portfolio Strategy & Business Development Frédéric Lombard, Senior Vice President, Chief Financial Officer Details for the Virtual Event The live webcast will be available at the following link: https://events.q4inc.c

Preliminary data from ongoing Phase 2 TELLOMAK trial of lacutamab demonstrated clinical activity in mycosis fungoides, presented at EORTC-CLTG annual meeting Preliminary Sezary syndrome lacutamab Phase 2 data to be presented at ASH 2022 Annual Congress Innovative ANKET™ pipeline will be on display at ASH 2022 Annual Congress Cash position of €151.4 million1 as of 30 September 2022, with anticipated cash runway into H2 2024 Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced its revenues and cash position for the first nine months of 2022. "Innate's strong financia

Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Monday, November 14, 2022, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2022. Speakers during the call will be: Mondher Mahjoubi, Chief Executive Officer Joyson Karakunnel, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Product Portfolio Strategy & Business Development Frédéric Lombard, Senior Vice President, Chief Financial Officer Details for the Virtual Event The live webcast will be available at the following link: https://events.q4inc.

Monalizumab and IPH5201 developed in collaboration with AstraZeneca advanced into Phase 3 and 2 clinical trials in lung cancer, triggering $55M in milestone payments Second preclinical asset based on Sanofi's proprietary multifunctional CROSSDILES® platform and Innate's proprietary multi-specific NK cell engager platform, ANKETTM targeting BCMA, selected by Sanofi for IND-enabling studies, with €3M milestone payment Cash position of €158.2 million1 as of June 30, 2022, anticipated cash runway into H2 2024 Conference call to be held today at 2:00 p.m. CEST / 8:00 a.m. EDT Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today reported its con

Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Thursday, September 15, 2022, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2022. Speakers during the call will be: Mondher Mahjoubi, Chief Executive Officer Joyson Karakunnel, Executive Vice President, Chief Medical Officer Frédéric Lombard, Senior Vice President, Chief Financial Officer Yannis Morel, Executive Vice President, Product Portfolio Strategy & Business Development Details for the Virtual Event The live webcast will be available at the following link: https://event.on24.

First patient dosed in monalizumab Phase 3 lung cancer trial, PACIFIC-9 sponsored by AstraZeneca, which triggered a $50 million milestone payment extending Company cash runway into 2024 Monalizumab data presented by AstraZeneca at AACR and in Journal of Clinical of Oncology Cash position to €131.7 million1 as of March 31, 2022 (not including the $50 million payment from AstraZeneca) Conference call to be held today at 2:00 p.m. CEST / 8:00 a.m. EDT Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today reported its consolidated financial results for the quarter ending March 31, 2022. "Again this quarter we made significant progress in our pip

Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Tuesday, May 10, 2022 at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2022. Speakers during the call will be: Mondher Mahjoubi, Chief Executive Officer Joyson Karakunnel, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Product Portfolio Strategy & Business Development Frédéric Lombard, Senior Vice President, Chief Financial Officer Details for the Virtual Event The live webcast will be available at the following link: https://event.on24.com/w

Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Thursday, March 24, 2022 at 2 p.m. CET / 9 a.m. ET, following the release of its financial results for the full year ending December 31, 2021. Speakers during the call will be: Mondher Mahjoubi, Chief Executive Officer Joyson Karakunnel, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Product Portfolio Strategy & Business Development Frédéric Lombard, Senior Vice President, Chief Financial Officer Details for the Virtual Event The live webcast will be available at the following link: https

Monalizumab in combination with durvalumab significantly delayed disease progression in AstraZeneca's randomized Phase 2 COAST study in unresectable, Stage III NSCLC, advancing to Phase 3 Pre-clinical data presented at SITC with Sanofi from the lead next-generation NK cell engager platform, ANKET™ targeting CD123 in acute myeloid leukemia Cash position of €141.8million1 as of September 30, 2021 Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced its revenues and cash position for the first nine months of 2021. "In the period, we continued to execute against our stra

Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Tuesday, November 16, 2021, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2021. Participating in the call will be Innate's Chief Executive Officer Mondher Mahjoubi, MD and Chief Medical Officer Joyson Karakunnel, MD, MSc, FACP. Details for the Virtual Event The live webcast will be available at the following link: https://event.on24.com/wcc/r/3492971/A9D12AE41D08D16F4096ACD3C27EC089 Participants may also join via telephone using the following dial in numbers: France: +33 8056 20 704 United

First data set from lacutamab TELLOMAK trial demonstrated encouraging 35% overall global response rate, including skin improvement in patients with mycosis fungoides that express KIR3DL2New pre-clinical data presented from next-generation NK cell engager platform, ANKET™, highlighted robust anti-tumor efficacy across several in vivo tumor models and manageable safety profileCash position of €159.4 million1 as of June 30, 2021Conference call to be held today at 2:00 p.m. CEST / 8:00 a.m. EDT MARSEILLE, France, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA ((Euronext Paris: IPH, NASDAQ:IPHA) ("Innate" or the "Company") today reported its consolidated financial results for the si

MARSEILLE, France, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA ((Euronext Paris: IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Wednesday, September 15, 2021, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2021. Participating in the call will be Innate's Chief Executive Officer Mondher Mahjoubi, MD, Chief Medical Officer Joyson Karakunnel, MD, MSc, FACP, and Chief Financial Officer Frédéric Lombard, MBA. Details for the Virtual Event The live webcast will be available at the following link: https://edge.media-server.com/mmc/p/bi2jkpjr Participants may also join via tel